How to Cite
Abstract
The human papilloma virus has been labeled as the first cause of cervical cancer cases in the world, that is why 3 different vaccines have been developed: the bivalent that covers against the serotypes 16 and 18, the quadrivalent for 6, 11, 16 y 18 and the nonavalent that covers against 6, 11, 16, 18, 31, 33, 45, 52 y 58; therefore, the majority of serotypes related to cancer and condylomatous injuries are covered with the vaccine. Two doses are indicated in a vaccination schedule for population among 9 and 15 years and three in the case of people among 15 and 26 years. Vaccines are secure, well tolerated and they are able to produce an accurate immune response. These do not have contraindication to be applied in immunocompromised patients but they have minor immune response than general population. Vaccines are not recommended during pregnancy but they are secure during breastfeeding. The vaccine against human papilloma virus has contributed to the reduction of illnesses associated to this virus which has evidenced its benefits in human health.
Keywords
References
David Springs. Gynecologic Malignancies. En J. Larry Jameson, Anthony S., Fauci, Dennis L. Kasper., Stephen L. Hauser., Dan L. Longo., Joseph Loscalzo (editor). Harrison's Principles of Internal Medicine. 20th Edition. United States: McGraw-Hill; 2018: p. 9-13.
Elmar A. Joura, M.D., Anna R. Giuliano, Ph.D., Ole-Erik Iversen, M.D., Celine Bouchard, M.D., et al. A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women. N Engl J Med [Internet]. 2015 [consultado 16 Marzo 2020]; 372(8): 711-723.
https://doi.org/10.1056/NEJMoa1405044
Christine Holschneider. Trastornos premalignos y malignos del cuello uterino. En Allan H. DeCherney (Editor). Diagnóstico y Tratamiento Ginecoobstétricos. 11 Edición. Ciudad de México: McGraw-Hill; 2014. p. 808-809.
Hoffman BL, Schorge JO, Bradshaw KD, Halvorson LM, Schaffer JI, Corton MM. Williams Ginecología [Internet]. New York, NY: McGraw-Hill; 2017 [revisión2017; consultado 12 Marzo 2020]. Disponible en: https://ezproxy.ucimed.com:2066/content.aspx?bookid=2162§ionid=165579611#1144484780
Lauri E. Markowitz, MD., Julianne Gee, MPH., Harrell Chesson, PhD., Shannon Stokley, DrPH. Ten Years of Human Papillomavirus Vaccination in the United States. Elsevier [Internet]. 2018 [consultado 10 Marzo 2020]; 18(2S): S3-S10. https://doi.org/10.1016/j.acap.2017.09.014
Leslie L. Clark, PhD, MS., Shauna Stahlman, PhD, MPH., Stephen B. Taubman, PhD. Human Papillomavirus Vaccine Initiation, Coverage, and Completion Rates Among U.S. Active Component Service Members, 2007-2017. MSMR [Internet]. 2018 [consultado 15 marzo 2020]; 25(9):9-14. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/30272988
Alain Luxembourg., Erin Moeller. 9-Valent human papillomavirus vaccine: a review of the clinical development program. Taylor & Francis [Internet]. 2017 [consultado 02 Marzo 2020]; 16 (11): 1119-1139. https://doi.org/10.1080/14760584.2017.1383158
Elissa Meites, Allison Kempe, Lauri E, Markowitz. Use of a 2-Dose Schedule for Human Papillomavirus Vaccination - Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR [Internet] 2016 [consultado 02 Marzo 2020]; 65(49):1405-1408. https://doi.org/10.15585/mmwr.mm6549a5
Aimée R. Kreimer, Rolando Herrero, Joshua N. Sampson, Carolina Porras, Douglas R. Lowy, Jhon T Schiller, et al. Evidence for single-dose protection by the bivalent HPV vaccine-Review of the Costa Rica HPV vaccine trial and future research studies. ELSEVIER [Internet] 2018 [consultado 02 Marzo 2020]; 36(32): 4774-4782. https://doi.org/10.1016/j.vaccine.2017.12.078
Claudia Robles, María de la Luz Hernández, Maribel Almonte. Alternative HPV vaccination schedules in Latin America. Salud Pública De México [Internet] 2018 [consultado 01 Marzo 2020]; 60(6): 693-702. https://doi.org/10.21149/9810
Linda O'Neal Eckert, Anna Barbara Mosciki. Human Papillomavirus Vaccination. ACOG [Internet] 2017 [consultado 29 Febrero 2020]; 129(6): 173-178. Disponible en: https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/06/human-papillomavirus-vaccination
Elissa Meites, MD., Peter G. Szilagyi, MD., Harrell W. Chesson, PhD., Elizabeth R. Unger, PhD, MD., José R. Romero, MD., Lauri E. Markowitz, MD. Supplemental information and guidance for vaccination providers regarding use of 9-valent HPV. CDC [Internet]. 2019 [consultado 12 Marzo 2020]; 68(32);698-702. Disponible en https://www.cdc.gov/mmwr/volumes/68/wr/mm6832a3.htm
Yoshiki Eto, Narcís Saubi, Pau Ferrer Joan Joseph. Design Chimeric Virus-Like Particle-based Vaccines for Human Papillomavirus and HIV: Lessons Learned. AIDSRev [Internet] 2019 [consultado 28 Febrero 2020]; 21(4): 218-232. https://doi.org/10.24875/AIDSRev.19000114
Tino F. Schwarz, Li-Min Huang, Alejandra Valencia, Falko Panzer, Cheng-Hsun Chiu, Annabelle Decreux. A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years. Taylor & Francis. [Internet] 2019 [consultado 02 Marzo 2020]; 15(7-8) 1970-1979. https://doi.org/10.1080/21645515.2019.1625644
Aimée R Kreimer, Ph.D., Frank Struyf, MD., Maria Rowena Del Rosario-Raymundo, MD., Prof. Allan Hildesheim, Ph.D., S Rachel Skinner, Ph.D., Prof. Sholom Wacholder, Ph.D., et al. Efficacy of Fewer than Three Doses of an HPV-16/18 AS04 adjuvanted Vaccine: Combined Analysis of Data from the Costa Rica Vaccine Trial and the PATRICIA Trial. PMC [Internet]. 2015 [consultado 07 Marzo 2020]; 16(7): 775-786. https://doi.org/10.1016/S1470-2045(15)00047-9
Laia Bruni, Beatriz Serrano, Xavier Bosch, Xavier Castellsagué. Vacuna frente al Virus del papiloma Humano. Eficacia y Seguridad.ELSEVIER [Internet] 2015 [consultado 02 Marzo 2020]; 33(5): 342-354. https://doi.org/10.1016/j.eimc.2015.03.018
Gina S. Ogilvie MD DrPH., Felicia Phan MPH., Heather N. Pedersen MPH., Simon R. Dobson MD., Monika Naus MD MHSc., Elizabeth M. Saewyc PhD RN. Population-level sexual behaviours in adolescent girls before and after introduction of the human papillomavirus vaccine. CMAJ [Internet]. 2018 [consultado 06 Marzo 2020]; 140(41): 1221-1226. https://doi.org/10.1503/cmaj.180628
Johannes a Bogaards, Jacco Wallinga, Ruud H Brakenhoff, Chris Meijer, Johannes Berkhof. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: Bayesian evidence synthesis. BMJ [Internet] 2015 [consultado 28 Febrero 2020]; 10(1136): 1-9. https://doi.org/10.1136/bmj.h2016
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2020 Array